Top Quality Benznidazole CAS NO (22994-85-0) Available at best selling price

Benznidazole (22994-85-0)

1. Chemical Identity: Benznidazole is a nitroimidazole derivative with the chemical formula C12H12N4O3 and the CAS number 22994-85-0. It belongs to the class of nitroheterocyclic compounds and is characterized by its benzene ring fused with a nitroimidazole moiety.

2. Pharmacological Significance: Benznidazole is an antiparasitic medication primarily used in the treatment of Chagas disease, a neglected tropical disease caused by the protozoan parasite Trypanosoma cruzi. It exerts its therapeutic effects by inhibiting the replication of the parasite, thereby reducing parasitic load and ameliorating disease progression.

3. Mode of Action: Upon administration, benznidazole undergoes metabolic activation within the parasite's cells, where it is converted into reactive metabolites that disrupt essential cellular processes. These metabolites induce oxidative stress and DNA damage, ultimately leading to parasite death.

4. Therapeutic Applications: Benznidazole is considered a first-line treatment for Chagas disease, particularly in the acute and early chronic stages of infection. It is effective in reducing parasitemia, preventing disease progression, and improving clinical outcomes. However, its efficacy in the chronic phase of Chagas disease is variable, and treatment may not always lead to parasite eradication.

5. Treatment Regimens: Benznidazole is typically administered orally as tablets or capsules. The duration of treatment varies depending on the stage of Chagas disease and the patient's age and clinical status. Treatment regimens may range from several weeks to months, with close monitoring of treatment response and potential adverse effects.

6. Safety and Tolerability: While benznidazole is generally well-tolerated, it may cause adverse effects in some individuals, including gastrointestinal symptoms (such as nausea, vomiting, and abdominal pain), dermatological reactions (such as rash and itching), and neurological manifestations (such as peripheral neuropathy and dizziness). Close monitoring and supportive care are essential to manage these side effects effectively.

7. Drug Interactions: Benznidazole may interact with other medications, particularly those metabolized by the cytochrome P450 enzyme system. Co-administration with drugs such as warfarin, phenytoin, and certain benzodiazepines may necessitate dose adjustments or monitoring of drug levels to prevent adverse interactions.

8. Pediatric and Special Populations: Benznidazole is also used in pediatric patients with Chagas disease, although dosing regimens may differ based on age and weight. Additionally, special considerations are warranted in pregnant women, as benznidazole may pose risks to the developing fetus. The decision to initiate treatment during pregnancy should weigh the potential benefits against the potential risks.

9. Resistance and Treatment Challenges: While benznidazole remains a cornerstone of Chagas disease treatment, challenges persist, including the emergence of drug-resistant parasite strains and limitations in efficacy, particularly in the chronic phase of the disease. Research efforts focus on identifying novel therapeutic targets and alternative treatment strategies to address these challenges.

10. Global Health Impact: Chagas disease remains a significant public health concern in endemic regions of Latin America, affecting millions of people and posing substantial economic and social burdens. Access to affordable and effective treatments, including benznidazole, is crucial for disease control and management, highlighting the importance of continued research, advocacy, and international collaboration in addressing this neglected tropical disease.